RecruitingPhase IIMale onlyEN originalProstate cancerEarly / localized

Efficacy and Safety of Simultaneous Integrated Boost Radiotherapy in HR/VHR Prostate Cancer With EPLNI

⚠️

This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.

About the trial

The aim of this study is to evaluate the efficacy and safety of hypofractionated simultaneous integrated boost volumetric arc radiation therapy (SIB - VMAT) for high-risk and very high-risk localized prostate cancer in terms of: 1. Acute and late gastrointestinal and genitourinary toxicities. 2. Evaluate the efficacy in terms of early bPFS. 3. Dosimetric evaluation in terms of target coverage and organs at risk sparing

Original English text from ClinicalTrials.gov

Who can (and can't) join

✓ Qualifies

  • Potwierdzony rozpoznaniem histologiczne adenocarcinoma prostaty
  • Rak klasyfikowany jako zaawansowany (wysoki lub bardzo wysoki stopień ryzyka) zgodnie z wytycznymi NCCN
  • Dobra funkcja pęcherza moczowego na początku leczenia
  • Przeprowadzone badania obrazowe: MRI prostaty, tomografia CT klatki piersiowej i brzucha, scyntygrafia kostna
  • Opcjonalnie badanie PET/CT aby wykluczyć przerzuty na całym ciele

✗ Disqualifies

  • Wcześniejsza radioterapia w obrębie miednicy
  • Historia choroby zapalno-obturacyjnej jelit lub aktywne zapalenie odbytnicy
  • Przerzuty nowotworu na inne narządy

Simplified criteria — AI translation

Trial details

Minimum age
18 Years
Last updated (source)
July 9, 2026
Sex
Male only

Therapies / drugs in trial

Locations (3)

Faculty of Medicine, Ain Shams University

Cairo, Egypt

Faculty of Medicine - Menoufia University

Shibīn al Kawm, Egypt

Faculty of Medicine - Sohag University

Sohag, Egypt

Trial contact

Contact information from ClinicalTrials.gov. Contact in English.

Share this trial

Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/10/2026.

You can help another person

We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.